anemia (5.4%), coronary atherosclerosis (4.5%), and congestive heart failure (3.5%). Similarly, the most commonly prescribed medications among CKD patients were furosemide (16.3%), atorvastatin (9.1%), lisinopril (9.0%), amiodipine (8.6%), levothyroxine (7.9%), metformin (7.8%), insulin (7.4%), atenolol (6.1%), and potassium replacement solutions (5.3%). Current smoking was the most common co-morbidities diagnosed among CKD patients. Early screening and treatment for these conditions may help lower the rate of progression of CKD.

PCK1

IMPACTS OF THE PREVENTIVE TREATMENT OF PATIENTS SUFFERING FROM RECURRENT CYSTITIS BY MEANS OF A STANDARD DRY CRANBERRY EXTRACT

Pierre Fabre, Bourgogne, France

OBJECTIVES: Assess the impacts of the preventive treatment of patients suffering from recurrent cystitis by means of a standard dry cranberry extract. METHODS: An observational, longitudinal and prospective assessment by Urologists as part of their professional everyday activity. RESULTS: Ninety-two female patients, with an average age of 53.9±18.9 years, were included in the study. These patients had been monitored for a period of 7 months (median). Before inclusion, 89 of the patients (96.7%) had been offered an antibiotic therapy. Depending on the patients, the factors that triggered their cystitis most frequently were: sexual relations (58.0%), alcohol consumption (27.6%) and diaphoresis (19.3%). The frequency and urgency of urination, the burning sensation upon urination, the inability to completely empty the bladder and sensation of heaviness in the pubic region were the five symptoms assessed every three weeks. On inclusion, the scores for each symptom were, respectively: 6.2; 6.1; 6.1; 3.1 and 4.6. The overall score was 28.9. After 3 months, the scores for each symptom were, respectively: 1.6; 1.9; 1.9; 0.4 and 0.7. The overall score was 7.1. The evolution of the overall score (p < 0.001) was significant, as was that of each respective symptom. The evolution percentage at 3 months was 74.7% (versus 96.7% on inclusion). CONCLUSIONS: The prevalence of urinary problems in subjects suffering from recurrent cystitis was halved after 3 months of treatment by means of a standard dry cranberry extract (96.7% versus 47.6%).

HEALTH CARE DECISION-MAKER’S CASE STUDIES POSTER SESSION

PCK1

CASE STUDY OF CREATING A FORMULARY MANAGEMENT PROCESS AT A COMPREHENSIVE CANCER CENTER IN BANGALORE, INDIA

Nayanapurkar A., Aji, Kumar E., Lal L5*

Bangalore Institute of Oncology, HCG Enterprises Ltd, Bangalore, Karnataka, India.
University of Texas MD Anderson Cancer Center, Houston, TX, USA

ORGANIZATION: Bangalore Institute of Oncology (BIO). PROBLEM OR ISSUE ADDRESSED: Pharmacy and Therapeutics committee’s responsibilities consist of developing policies and frameworks to develop an effective formulary taking into account both efficacy and cost considerations. In the Indian pharmaceutical environment, drug manufacturers compete for market share with a single institution, creating inefficiencies in inventory management and the overall pharmaceutical budget. GOALS: The purpose of this project was to create a formulary for the Bangalore Institute of Oncology (BIO), taking into account both cost and efficacy considerations, that would maintain physician autonomy. Preliminary ABC analysis, also known as a Pareto analysis, was conducted to identify items which have a significant impact on the overall inventory costs and what, by including and rank areas for improvement and management interventions. OUTCOMES (ABCD) DECISION: The institutional ABC analysis was performed at the period of October 2006 to September 2007. Pharmaceutical items were valued (item cost multiplied by quantity issued/consumed in period) with the results subsequently ranked. IMPLEMENTATION STRATEGY: The total pharmacy budget for the fiscal year was 15.89 Crore Rupees (Rs) (3.96 million US dollars, based on 40:1 exchange rate) with a resulting margin of 3.51 Crore Rupees (Rs) ($877,500), which consisted of 1033 different products from 247 manufacturers. The ABC analysis revealed that 48 medications made up 85% of the total budget, with bortezomib being the highest oncology contributor and mepremab being the highest non-oncology contributor. Analysis of procurement within the 15 oncology products revealed that there were 29 manufacturers with 95 different brands, and for the 13 non oncology products, there were 14 manufacturers with 20 different brands. Based on this analysis, consolidation of drug products and drug manufacturers was considered as an intervention for formulary management by the Pharmacy and Therapeutics Committees. Three different options were considered by the committee. Option 1 consolidates to only a single brand based on the highest margin, which would improve the present margin by 46% from 3.51 Crore Rs ($877,500) to 5.15 Crore Rs ($1,287,500). Option 2 consolidates to having two brands, one from the preferred vendor and the other from the innovator/premier vendor, which would improve the margin by 24% to 4.36 Crore Rs ($1,090,000). Option 3 was chosen as the basis for the creating the institutional formulary, due to physician flexibility, patient affordability, and improvements to the margin. RESULTS: The pharmaceutical company Dr Reddy was selected as the preferred vendor for the creation of the formulary and Option 3 was applied to all of the following pharmaceuticals: monoclonal antibodies; oral chemotherapy; intravenous chemotherapy; hormonal agents; and supportive care agents (13), for a total of 82 separate chemical entities. Of the total 82 chemical entities, 43 (52.4%) have one brand available, 29 (35.4%) have two brands available, and 10 (12.2%) have three brands available. The preferred vendor was utilized for 18 of these products. If the same total quantity is purchased again in 2008, the total purchase price will be 54.15 Crore Rs ($13,531,047) with a resulting margin of 20.13 Crore Rs ($5,013,454). LESSONS LEARNED: Consolidation of the pharmaceutical products and creation of a formulary results in higher than expected margin, even when the same purchase quantity is applied. Market competition forces appear to work better in an environment of a closed formulary system.

PCK2

THE HOSPITAL AS IMPORTANT SOURCE OF INFORMATION REGARDING CHARACTERISTICS OF HEALTH CARE USERS

Ogura LM*, Serrano E, Sena E

Vila Velha Hospital Vila Velha, Espirito Santo, Brazil

ORGANIZATION: Vila Velha Hospital (VHH), Vila Velha, Espirito Santo, Brazil. PROBLEM OR ISSUE ADDRESSED: To assure client space and fidelity in the market of health services through novel strategies able to supply health care providers with information about their clients and service costs at hospitals in the metropolitan region of Vitoria-Es, Brazil. GOALS: 1-Semestral increase of 30% in the number of clients referred for consultation at VHH and their fidelity as a result of the good quality of services. 2-Semestral increase of 20% in VHH services required from health care providers. OUTCOMES ITEMS USED IN THE DECISION: Regarding the opinion of clients and health care providers about the ideal health services were considered in the final decision. This information was obtained from PROAHA (Program of Advanced Studies in Hospital Administration and Health Management) and from CHQ (Program of Quality Control of Medical Services). IMPLEMENTATION STRATEGY: Analysis of patient stay at the hospital and its total cost, considering age, site and disease of the client at VHH. All diseases described in ICD (International Classification of Diseases) were classified in acute, chronic and accidental, according to the duration of disease, loss of function, treatment type and length, and recurrence probability. RESULTS: The data obtained allowed the comprehension of characteristics of clients seen at VHH, and also allowed the proper estimation of treatment costs for various pathologies and the development of a cost curve per pathologies, materials and medications. LESSONS LEARNED: The data used to identify clients specificities allows price negotiation in a more secure and transparent way for both the hospital and the health care providers, and allows a more efficient handling of financial resources.

PCK2

HTA PROCEDURES IN DRUG REIMBURSEMENT PROCESS IN POLAND. EVOLUTION OF RECOGNITION THE ROLE OF AGENCY OF HEALTH TECHNOLOGY ASSESSMENT (AHTAPOL) BY POLICY MAKERS

Prawdzicki M, Matusiak-Wojcik M

Agency for Health Technology Assessment, Warsaw, Poland

ORGANIZATION: Agency of Health Technology Assessment Warsaw, Poland. PROBLEM OR ISSUE ADDRESSED: Need to supply safe and most effective drugs and treatments to services and devices for publicly insured inhabitants through different mechanisms of spending public sources. GOALS: (1) Development a health technology assessment procedures and incorporating its results into decision-making process of public sources. (2) Setting priorities of assessment areas and optimization of decision making to health benefits financed from public means reimbursement criteria. (3) Providing sufficient information for making decisions. OUTCOMES ITEMS USED IN THE DECISION: There were different measurements performed during planning, implementing and revising process of development of AHTAPol. Measures were elaborated parallel by national and international experts. IMPLEMENTATION STRATEGY: AHTAPol was established on 2006 as a governmental organization whose aims are: assessment of medical procedures – health technologies; elaboration, verification, gathering and dissemination of information about HTA results of such assessments, methodology and support of guidelines development made based on them; elaboration of recommendations for the Minister of Health concerning financing health technologies from public means (the role of the Consultative Council); collaboration with other authorities and organization acting in health care system and performing other duties delegated by the Minister of Health (MoH) of Poland. One of the first actions of AHTAPol was related to delegation of MoH for development the basic benefit package. For the estimation of budget needed to services included into benefit package the costs calculating program was designed and pilot activities were performed. And finally stage of assessment and appraisal process led to recommendation for decision of MoH. These actions were supported by development department focused on analytical part and independent body – Consultative Council acting as an appraisal committee. RESULTS: Involvement of AHTAPol in activities related to based benefit package was limited to development of central medical services (with exception of diagnoses and professional specialties) data-base. Costs calculation of these services was not started. Engagement of nationally recognized experts supported by AHTAPol ended on development national cost calculating project. This project most probably will start in 2009. The most expected by policy-makers, public and patients’ activities of AHTAPol nowadays is involvement on the process of drug and modern medical technology reimbursement by elaboration of recommendations for decision of MoH. Organizational respond of AHTAPol resulted at the number of recommenda- tion: 13 in 2007 and 81 in 2008. In 2009 is planned over 300. LESSONS LEARNED: